Diabetes Management Devices Market Size, Share, Growth and Industry Analysis, By Type (Blood Glucose Monitoring Device and Insulin Delivery Systems), By Application (Hospitals, Clinics and Others), Regional Outlook, and Forecast From 2025 To 2033

Last Updated: 02 June 2025
SKU ID: 20926986

Trending Insights

Report Icon 1

Global Leaders in Strategy and Innovation Rely on Our Expertise to Seize Growth Opportunities

Report Icon 2

Our Research is the Cornerstone of 1000 Firms to Stay in the Lead

Report Icon 3

1000 Top Companies Partner with Us to Explore Fresh Revenue Channels

DIABETES MANAGEMENT DEVICES MARKET REPORT OVERVIEW

The global diabetes management devices market size was valued at approximately USD 49.45 billion in 2024 and is expected to reach USD 90.91 billion by 2033, growing at a compound annual growth rate (CAGR) of about 7% from 2025 to 2033.

Due to a problem with the synthesis of the hormone insulin, which regulates blood glucose levels, diabetes is an illness that manifests when blood glucose levels rise over normal levels. People's food consumption provides blood glucose, which serves as their primary source of energy. Blood sugar levels are kept stable by the pancreatic hormone insulin. Diabetes is brought on by a problem with the body's ability to synthesize insulin, which prevents it from controlling the blood glucose level. The glucose levels of a diabetic patient are monitored via diabetes management devices. Throughout the day, a diabetic patient's blood glucose is tracked and monitored by a continuous glucose monitor (CGM), a medical gadget. People with diabetes can utilize this wearable technology to better control their glucose levels, making it particularly helpful for them.

COVID-19 Impact: Increase in Utilization of the Devices due to the High Number of Patients Hospitalized with Diabetes

The global COVID-19 pandemic has been unprecedented and staggering; with the diabetes management devices market experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden spike in CAGR is attributable to demand returning to pre-pandemic levels once the pandemic is over.

The market for diabetic management devices has been significantly influenced by the COVID-19 epidemic. The significance of diabetes management devices has been highlighted by the high frequency of diabetes in patients hospitalized with COVID-19 virus and the knowledge that better glycemic control may improve outcomes and shorten the duration of stay in individuals with SARS-CoV-2.Through virtual consultations between medical professionals and people with diabetes, as well as the utilization of diabetic technologies, the pandemic also highlighted prospects for advancing and spreading innovations in the provision of diabetes care. As well as removing numerous long-standing legislative restrictions, crisis management has sparked an extraordinary interest in distant treatment among both patients and clinicians. For the length of the epidemic, hospitals utilized continuous glucose monitoring equipment and personal blood glucose meters, thanks to a decision by the US Food and Drug Administration. Therefore, the global market for diabetic management devices grew faster after the COVID-19 epidemic.

LATEST TRENDS

Latest AID System Utilized to Continuously Track Blood Sugar Levels

The partnership between Abbott, CamDiab, and Ypsomed to create and market an integrated automated insulin delivery (AID) system across European nations was announced in April 2022. The linked, intelligent wearable device is intended to continuously track a person's blood sugar levels, automatically modify, and give the appropriate dose of insulin at the appropriate moment, doing away with the need for guessing in insulin administration.

Diabetes Management Devices Market Share, By Application, 2033

ask for customizationRequest a Free sample to learn more about this report

DIABETES MANAGEMENT DEVICES MARKET SEGMENTATION

  • By Type

Based on type, the market is distributed into Blood Glucose Monitoring Device and Insulin Delivery Systems

  • By Application

Based on application, the market is divided into Hospitals, Clinics and Others

DRIVING FACTORS

Technological Developments to Increase Sensor Accuracy in Glucose Oxidase

Sensors for continuous glucose monitoring measure blood sugar levels using glucose oxidase. When glucose is turned into hydrogen peroxide by glucose oxidase, it combines with the platinum inside the sensor to provide an electrical signal that is sent to the transmitter. The most crucial component of devices for continuous glucose monitoring is a sensor. During the forecast period, segment expansion is anticipated to be fueled by technological developments that increase sensor accuracy.

Unhealthy Lifestyles and Obesity act as Driving Factors for the Market of Diabetes Management Devices

Another reason driving the diabetes management devices market growth is the rise in the incidence of diabetes brought on by obesity, aging, and unhealthy lifestyles. One of the main causes of diabetes is obesity. The WHO estimates that in 2016, 650 million adults worldwide were considered obese. About 2 billion adults worldwide were considered overweight in 2016. An increase in the prevalence of diabetes is being attributed to risk factors like obesity and overweight. As a result, risk factors like smoking, being overweight or obese, and having high cholesterol levels are predicted to increase the prevalence of diabetes and increase the demand for diabetes management devices.

RESTRAINING FACTORS

Accuracy of the Reading on the Devices Might be Wrong as it reads the Interstitial Fluid and Not the Bloodstream

The blood glucose monitors don't always provide reliable readings. The interstitial fluid, not the bloodstream, is used by the sensor to detect a person's blood glucose because technology is currently not up to par. In addition to this issue, depending solely on sensor readings might be risky because they may indicate one result while a conventional blood test indicates another. So that they may be discouraged from purchasing diabetes management devices.

DIABETES MANAGEMENT DEVICES MARKET REGIONAL INSIGHTS

North America to Dominate the Market due to Rapidly Growing Number of Patients with Diabetes and Favorable Government Policies

Revenue in North America exceeded the estimated amount. This is mainly because there are more people with diabetes in North America as a result of stress, poor diets, and obesity. By 2028, there will be an increase in the number of diabetic patients in North America, up from the current total. In 2021, there were a large portion of diabetic patients in only the United States. The diabetes management devices market share in North America is dominated by the United States. The development of the diabetes management devices in this region is additionally aided by favorable government reimbursement policies and a sophisticated healthcare system. The United States' fast rising prevalence and incidence of diabetic patients as well as healthcare spending point to an increase in the use of diabetes management products.

KEY INDUSTRY PLAYERS

The Major Players of this Market are Involved in Intense Competition and Expansion into New Markets to Broaden their Shares

The diabetes management devices market has a low level of large and generic competitors. Several large companies, like Dexcom Medtronics, Abbott, and more generic businesses like Roche, Arkray, and Ascensia, respectively, dominate the markets for CGM and SMBG devices. A few multinational and domestic businesses, including Novo Nordisk, Eli Lilly and Company, Medtronic, and Becton Dickinson and Company, among others, are examined in the competitive landscape for insulin devices. As each competitor tries to create a brand-new device and sell it for a reasonable price, there is intense competition among the players. Players are also expanding into new markets, particularly emerging economies where demand is much higher than supply, in an effort to boost their market shares.

List Of Top Diabetes Management Devices Companies

  • Abbott Laboratories (U.S.)
  • Dexcom (U.S.)
  • Roche (Switzerland)
  • Lifescan (U.S.)
  • Medtronic (Ireland)
  • Terumo (Japan)
  • B. Braun Melsungen (Germany)
  • BD (U.S.)
  • Ascensia (Bayer) (U.S.)
  • Senseonics Holdings (U.S.)
  • Johnson & Johnson (U.S.)
  • Eli Lilly (U.S.)
  • Novo Nordisk (Denmark)
  • Sanofi (France)
  • Ypsomed Holding (Switzerland)

REPORT COVERAGE

This report covers the diabetes management devices market. The CAGR expected to be in during the forecast period, and also the USD value in 2022 and what it is expected to be in 2028. The effect COVID-19 had on the market in the beginning of the pandemic. The latest trends taking place in this industry. The factors that are driving this market as well as the factors that are restraining the growth of industry. The segmentation of this market based on type and applications. The region leading in the industry and why they will continue to do so during the forecast period. Further, the key market players, what all is being done by them to stay ahead of their competition as well as retain their market positions. All these details are covered in the report.

Diabetes Management Devices Market Report Scope & Segmentation

Attributes Details

Market Size Value In

US$ 49.45 Billion in 2024

Market Size Value By

US$ 90.91 Billion by 2033

Growth Rate

CAGR of 7% from 2024 to 2033

Forecast Period

2025-2033

Base Year

2024

Historical Data Available

Yes

Regional Scope

Global

Segments Covered

By Types

  • Blood Glucose Monitoring Device
  • Insulin Delivery Systems

By Application

  • Hospitals
  • Clinics
  • Others

FAQs